GBNHF vs. ACON, BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, and TALKW
Should you be buying Greenbrook TMS stock or one of its competitors? The main competitors of Greenbrook TMS include Aclarion (ACON), Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), and Talkspace (TALKW). These companies are all part of the "healthcare" industry.
Greenbrook TMS vs.
Greenbrook TMS (NASDAQ:GBNHF) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
Greenbrook TMS has a net margin of -70.28% compared to Aclarion's net margin of -12,845.05%. Greenbrook TMS's return on equity of 0.00% beat Aclarion's return on equity.
7.5% of Aclarion shares are held by institutional investors. 21.7% of Greenbrook TMS shares are held by company insiders. Comparatively, 1.5% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Aclarion has lower revenue, but higher earnings than Greenbrook TMS.
In the previous week, Aclarion had 4 more articles in the media than Greenbrook TMS. MarketBeat recorded 4 mentions for Aclarion and 0 mentions for Greenbrook TMS. Greenbrook TMS's average media sentiment score of 0.00 beat Aclarion's score of -0.12 indicating that Greenbrook TMS is being referred to more favorably in the media.
Aclarion received 4 more outperform votes than Greenbrook TMS when rated by MarketBeat users.
Aclarion has a consensus target price of $1.30, suggesting a potential upside of 2,973.29%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Greenbrook TMS.
Greenbrook TMS has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Summary
Aclarion beats Greenbrook TMS on 8 of the 15 factors compared between the two stocks.
Get Greenbrook TMS News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBNHF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GBNHF vs. The Competition
Greenbrook TMS Competitors List
Related Companies and Tools
This page (NASDAQ:GBNHF) was last updated on 1/21/2025 by MarketBeat.com Staff
Free GBNHF Stock Alerts